Beyond the Rebate: How Executives Can Better Manage Pharmacy Spend

The landscape of employer-sponsored healthcare is experiencing continued inflationary pressures, largely driven by misaligned vendor incentives and the rapid rise in pharmacy spend. As high-cost specialty medications and GLP-1 agonists become more prevalent, traditional methods of evaluating PBMs are failing to provide the accurate cost estimates that plan sponsors and payers need. The industry's default fix - chasing deeper discounts and bigger rebate checks - obscures the true drivers of plan performance.

Download our whitepaper, Beyond the Rebate: How Executives Can Better Manage Pharmacy Spend, to learn:
‍

• Why the rebate-first procurement model accounts for only ~30% of future drug costs, and what drives the other 70%.
• How drug mix and clinical levers like prior authorization and refill logic are the highest predictors of total plan spend.
• The case for shifting from AWP-based pricing to transparent, acquisition-cost benchmarks, like NADAC.
• How to evaluate emerging guarantee models, from utilization guarantees, to PMPM arrangements, to level-funded structures.